Daiwa Capital Downgrades Bristol-Myers Squibb to Neutral, Lowers Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Daiwa Capital analyst Narumi Nakagiri has downgraded Bristol-Myers Squibb (NYSE:BMY) from Outperform to Neutral and lowered the price target from $68 to $54.
November 02, 2023 | 3:28 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Bristol-Myers Squibb has been downgraded by Daiwa Capital from Outperform to Neutral, with a lowered price target from $68 to $54.
The downgrade from Outperform to Neutral by Daiwa Capital indicates a less optimistic outlook for Bristol-Myers Squibb. The lowered price target from $68 to $54 suggests that the analyst believes the stock is currently overvalued, which could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100